Bavarian Nordic receives special designation from FDA
The US Food and Drug Administration has awarded the so-called Breakthrough Therapy Designation to Bavarian Nordic’s vaccine candidate for RSV prevention in adults aged 60 years or older.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
Danish Bavarian Nordic has received a particularly sought-after special regulatory status from the US Food and Drug Administration (FDA), the company announces in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Analyst thinks RSV vaccine market could reach over USD 10bn
For subscribers
